Health-related Quality of Life in Children and Adolescents After Successful Treatment of Chronic Hepatitis C With Sofosbuvir/Velpatasvir: One-year Outcomes

Pediatr Infect Dis J. 2025 May 1;44(5):405-410. doi: 10.1097/INF.0000000000004675. Epub 2024 Dec 20.

Abstract

Background and aims: The aim of this study was to assess the health-related quality of life (HRQL) of children with chronic hepatitis C (CHC) at 1 year after the effective treatment with sofosbuvir/velpatasvir (SOF/VEL).

Methods: All 50 patients treated for CHC with a fixed dose SOF/VEL in the noncommercial, nonrandomized, open-label PANDAA-PED study achieved sustained virologic response at 12 weeks after the end of treatment. Evaluation of HRQL at 1-year posttreatment was compared with the baseline (before the treatment) assessment. KIDSCREEN-27 questionnaires, which included 5 dimensions of HRQL, for child self-reporting and parent proxy reporting were used. The normal range for the population was set to T values of 40-60 points. Child-parent agreement was analyzed using the intraclass correlation coefficient (ICC).

Results: Mean T values were within the normal range for all HRQL dimensions. A significant improvement in "autonomy & parent relation" in children's self-assessment (from 48.3 to 51.5, P = 0.03) was observed. In parent proxy assessment, a significant decrease occurred in "school" dimension (from 49.5 to 45.8, P = 0.03), which was not revealed at 3-month posttreatment. Older age was associated with worse HRQL scores in all dimensions. Evaluation of the ICC for child self-reports versus parent proxy reports revealed poor-to-moderate agreement for most single measures, lower than at 3-month posttreatment analysis.

Conclusions: This is the first study to present the long-term influence of treatment with direct-acting antivirals on patient-reported outcomes in children. At 1 year after effective treatment with SOF/VEL, an improvement in some areas of children's well-being was revealed, which may indicate also some patient-reported outcomes benefits of direct-acting antiviral therapy. Despite the improvement in the child self-report of "autonomy & parent relation," there was a more pronounced discrepancy between children self-reports and parents proxy reports in all dimensions of HRQL. Older patients' age correlated with worse HRQL assessment. If this finding is mediated by the duration of hepatitis C virus infection, it would support recommendation for the treatment of younger children.

Keywords: children; health-related quality of life; hepatitis C virus; sofosbuvir/velpatasvir.

MeSH terms

  • Adolescent
  • Antiviral Agents* / therapeutic use
  • Benzimidazoles
  • Benzopyrans
  • Carbamates* / therapeutic use
  • Child
  • Child, Preschool
  • Female
  • Hepatitis C, Chronic* / drug therapy
  • Hepatitis C, Chronic* / psychology
  • Heterocyclic Compounds, 4 or More Rings* / therapeutic use
  • Humans
  • Male
  • Quality of Life*
  • Sofosbuvir* / therapeutic use
  • Surveys and Questionnaires
  • Treatment Outcome

Substances

  • Sofosbuvir
  • Carbamates
  • Antiviral Agents
  • Heterocyclic Compounds, 4 or More Rings
  • velpatasvir
  • Benzimidazoles
  • Benzopyrans